PIK3CD and activated PI3K-delta syndrome: APDS patients carry heterozygous gain-of-function mutations in PIK3CD (APDS1) or loss-of-function mutations in PIK3R1 (APDS2), resulting in enhanced PI3K and activated downstream Akt/mTOR signaling.